NEW HAVEN, Conn.--(BUSINESS WIRE)--May 4, 2006--RHEI Pharmaceuticals, Inc. and Flamel Technologies, S.A. (Nasdaq:FLML - News) today announced that RHEI has licensed from Flamel the exclusive right to market Asacard® in the Greater China region (including China, Taiwan, Hong Kong and Macau). Asacard® is a controlled release formulation of aspirin. Flamel will manufacture commercial supply of the product at its facilities in Pessac, France. Financial terms were not disclosed.
